問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃維俊

Recruiting

List

12Cases

2026-01-29 - 2031-11-15

Phase II/III

Active
AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

  • Condition/Disease

    Moderate to Severe Chronic Obstructive Pulmonary Disease

  • Test Drug

    PF-07275315 Placebo

Participate Sites
7Sites

Recruiting7Sites

2026-05-01 - 2027-07-28

Phase III

Not yet recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

  • Condition/Disease

    Narcolepsy Type 2

  • Test Drug

    ALKS 2680

Participate Sites
3Sites

Recruiting3Sites

2026-05-01 - 2027-07-28

Phase III

Not yet recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

  • Condition/Disease

    Narcolepsy Type 1

  • Test Drug

    ALKS 2680

Participate Sites
3Sites

Recruiting3Sites

2024-05-31 - 2027-05-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-01-31 - 2028-01-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-01-22 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2025-10-01 - 2028-12-31

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2025-12-11 - 2031-06-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-10-01 - 2027-10-01

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2024-05-16 - 2026-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB